Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Revolution Medicines has begun treating patients in its Phase 3 RASolute 309 trial for its drug daraxonrasib (RASONQUE™) combined with zoldonrasib. The trial is evaluating the combination as a first-line treatment for metastatic RAS G12D pancreatic cancer.
On Wednesday, Kura Oncology (NASDAQ: KURA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Kura Oncology reported $9.1 million in n